Published in Gerontology on July 03, 2015
Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma. Dis Markers (2015) 0.75
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev (2006) 2.10
A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev (2009) 1.98
Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano (2011) 1.90
Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res (2007) 1.87
Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir (2012) 1.15
NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res (2008) 1.02
Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer (2009) 1.01
Cell-based analysis of structure-function activity of threonine aspartase 1. J Biol Chem (2010) 0.98
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget (2012) 0.94
Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic (2006) 0.93
Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol (2012) 0.90
The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol (2007) 0.90
Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors. PLoS One (2011) 0.89
Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int J Cancer (2007) 0.88
Histone deacetylase inhibitors block IFNγ-induced STAT1 phosphorylation. Cell Signal (2012) 0.88
Nuclear receptors in head and neck cancer: current knowledge and perspectives. Int J Cancer (2010) 0.87
Human PAPS synthase isoforms are dynamically regulated enzymes with access to nucleus and cytoplasm. PLoS One (2012) 0.86
No king without a crown--impact of the nanomaterial-protein corona on nanobiomedicine. Nanomedicine (Lond) (2015) 0.84
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int J Cancer (2007) 0.83
Differential regulation of PML-RARα stability by the ubiquitin ligases SIAH1/SIAH2 and TRIAD1. Int J Biochem Cell Biol (2011) 0.83
Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo. FASEB J (2012) 0.81
An update on the pathobiological relevance of nuclear receptors for cancers of the head and neck. Histol Histopathol (2010) 0.81
The importin-alpha/nucleophosmin switch controls taspase1 protease function. Traffic (2011) 0.80
Expression analysis suggests a potential cytoprotective role of Birc5 in the inner ear. Mol Cell Neurosci (2010) 0.79
Cloning and functional characterization of the guinea pig apoptosis inhibitor protein Survivin. Gene (2010) 0.79
Translocation Biosensors - Cellular System Integrators to Dissect CRM1-Dependent Nuclear Export by Chemicogenomics. Sensors (Basel) (2009) 0.79
A tailor-made specific anion-binding motif in the side chain transforms a tetrapeptide into an efficient vector for gene delivery. Angew Chem Int Ed Engl (2015) 0.79
Overexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cells. PLoS One (2012) 0.76
Evolutionary divergence of Threonine Aspartase1 leads to species-specific substrate recognition. Biol Chem (2015) 0.76
Targeting Taspase1 for cancer therapy--letter. Cancer Res (2012) 0.75